Cephalon, Barr Settle Fentora Patent Battles

By Hilary Russ

Law360, New York (November 13, 2009, 4:56 PM ET) -- Cephalon Inc. and Barr Pharmaceuticals LLC have called a truce in their legal battles over the cancer painkiller Fentora.

In a filing Thursday with the U.S. Securities and Exchange Commission, Cephalon said it had entered into a binding agreement-in-principle with Barr, along with Barr Laboratories Inc, to settle its pending patent infringement lawsuit over Barr's generic version of the fentanyl buccal tablet.

Under the terms of the deal, Cephalon agreed to grant Barr a nonexclusive, royalty-free right to market and sell a generic version of Fentora...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles